Acoramidis ATTR Cm denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for acoramidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Acoramidis as Duplicate Therapy for ATTR-CM — and How to Appeal

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious, progressive condition. Acoramidis is a transthyretin stabilizer — a mechanism-based therapy targeting the underlying disease process. A "duplicate therapy" denial typically means Aetna has flagged that the patient is already receiving another agent it considers to have a similar mechanism or indication, most commonly another TTR stabilizer or a TTR silencer.

However, agents in the ATTR-CM space differ in mechanism of action (stabilization vs. silencing vs. degradation), route of administration, pharmacology, and the specific patient populations for which they are indicated. "Duplicate" does not automatically mean clinically interchangeable. Your appeal should make that distinction explicit.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, a duplicate-therapy denial must be grounded in a clinical determination that the two agents are truly interchangeable for your case. You have the right to a full-and-fair internal review and, if that fails, an independent external review — typically available within four months of the final internal denial. An expedited track is available for urgent situations.

## Your Appeal Timeline

• Internal appeal: File within 180 days of the denial notice (confirm the exact deadline on your Explanation of Benefits).
• External review: File within approximately four months of the final internal denial.
• Expedited option: Request this track if delay poses significant health risk.

## Documentation to Gather

1. Diagnosis confirmation: Cardiac imaging, biopsy, or genetic/technetium-scan documentation confirming ATTR-CM subtype (wild-type vs. hereditary) and current disease stage. 2. Current medication list with dates and rationale: Documentation of what the patient is currently taking, when it was started, and the clinical rationale for each agent. 3. Mechanism distinction: Ask your cardiologist to provide a written explanation of how acoramidis differs mechanistically from any currently prescribed agent, and why those differences are clinically meaningful for this patient. 4. Prescriber medical-necessity letter: A letter from the treating cardiologist explaining why acoramidis is not duplicative — specifically addressing why the concurrent agent does not cover the same clinical need. 5. Applicable guideline reference: Note alignment with the relevant cardiology guideline organization's (e.g., ACC/AHA) position on ATTR-CM management, including any guidance on combination or sequencing of therapies.

## Criteria-Mapping Structure

Obtain Aetna's published medical policy for acoramidis (or the relevant Clinical Policy Bulletin). For each criterion cited in the duplicate-therapy denial, map it to a specific chart fact:

| Policy Criterion | Supporting Evidence | |---|---| | Confirmed ATTR-CM diagnosis | [Imaging/biopsy date, result] | | Current therapy identified | [Agent, start date, clinical purpose] | | Mechanistic or clinical distinction from current therapy | [Cardiologist letter] | | Medical necessity for acoramidis specifically | [Prescriber letter, guideline reference] |